Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors - Kris, M G; Camidge, D R; Giaccone, G (Ann Oncol, 2015)